Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2026)

Supernus Pharmaceuticals (SUPN) has 4 years of Asset Writedowns and Impairment data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 231.81% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 63.56% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 78.59% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $1.8 million, up from $672000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for SUPN reached as high as $20.2 million in Q4 2023 and fell as low as -$239000.0 in Q3 2025.
• Historically, Asset Writedowns and Impairment has averaged $3.3 million across 4 years, with a median of $825000.0 in 2024.
• Across the five-year window, Asset Writedowns and Impairment plunged 724.14% in 2025 and surged 231.81% in 2026, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $20.2 million in 2023, then sank by 65.93% to $6.9 million in 2024, then slumped by 90.24% to $672000.0 in 2025, then surged by 170.09% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $1.8 million in Q1 2026, $672000.0 in Q4 2025, and -$239000.0 in Q3 2025.